A 10-year follow-up of infliximab monotherapy for refractory uveitis in Behçet’s syndrome
Abstract Infliximab (IFX) was the first biologic introduced for refractory uveitis treatment in Behçet’s syndrome (BS). However, there have been few reports on the safety and efficacy of IFX monotherapy over follow-up periods of more than 10 years. This retrospective study evaluated the 10-year safe...
Guardado en:
Autores principales: | Noe Horiguchi, Koju Kamoi, Shintaro Horie, Yuko Iwasaki, Hisako Kurozumi-Karube, Hiroshi Takase, Kyoko Ohno-Matsui |
---|---|
Formato: | article |
Lenguaje: | EN |
Publicado: |
Nature Portfolio
2020
|
Materias: | |
Acceso en línea: | https://doaj.org/article/c2c6986109f94e438d98391d829b7e87 |
Etiquetas: |
Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
|
Ejemplares similares
-
Association between subfoveal choroidal thickness and leakage site on fluorescein angiography in Behçet’s uveitis
por: Shintaro Shirahama, et al.
Publicado: (2019) -
Infliximab in treatment of idiopathic refractory childhood pyoderma gangrenosum (PG)
por: Salehzadeh F, et al.
Publicado: (2019) -
Features of systemic cytokine production in Behcet's disease associated with uveitis without ocular lesions
por: E. S. Sorozhkina, et al.
Publicado: (2021) -
EFFECT OF HUMAN HERPES VIRUS REACTIVATION ON SYSTEMIC CYTOKINE PRODUCTION IN PATIENTS WITH BEHCET’S DISEASE AND UVEITIS
por: G. I. Krichevskaya, et al.
Publicado: (2021) -
Efficacy of infliximab in refractory Behçet’s disease-associated and idiopathic posterior segment uveitis: a prospective, follow-up study of 50 patients
por: Cantini F, et al.
Publicado: (2011)